Gilead Sciences, Inc. $GILD Shares Sold by Royal Fund Management LLC

Royal Fund Management LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 79.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,876 shares of the biopharmaceutical company’s stock after selling 7,305 shares during the quarter. Royal Fund Management LLC’s holdings in Gilead Sciences were worth $261,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in GILD. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences during the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC increased its holdings in shares of Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter valued at $26,000. Wealth Preservation Advisors LLC boosted its stake in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Ares Financial Consulting LLC acquired a new position in shares of Gilead Sciences in the 4th quarter worth $28,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. This represents a 2.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,000 shares of company stock valued at $8,687,140 in the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $131.28 on Friday. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The stock has a market cap of $162.99 billion, a PE ratio of 17.89 and a beta of 0.32. The business has a fifty day simple moving average of $129.70 and a 200-day simple moving average of $135.91.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GILD. Truist Financial cut their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $157.93.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: European regulators issued a positive opinion supporting expanded use of Trodelvy with Keytruda in certain patients with advanced triple-negative breast cancer. The decision strengthens Gilead’s oncology opportunity and may improve confidence in Trodelvy’s growth prospects. Gilead Sciences Following Trodelvy Progress and a Fair Value Debate
• Positive Sentiment: UBS reiterated a Buy rating and a $175 price target, citing Gilead’s long-acting HIV pipeline and advances in pre-exposure prophylaxis (PrEP) as drivers of durable growth. HIV franchise strength, Yeztugo expectations and oncology progress are also highlighted ahead of the earnings report. UBS Reiterates Buy on Gilead
• Neutral Sentiment: Analyst coverage remains generally bullish, and several valuation articles describe GILD as potentially inexpensive after its strong five-year performance. However, investors remain divided over how much of the company’s future growth is already reflected in the shares. Do Wall Street Analysts Like Gilead Sciences Stock?
• Neutral Sentiment: Second-quarter earnings previews focus on revenue, earnings and operating metrics rather than reporting new results. A favorable quarter could clarify recent estimate and valuation concerns, while investors are likely to watch HIV sales, Yeztugo adoption potential, Trodelvy and cell therapy performance closely. Gilead to Report Q2 Earnings
• Negative Sentiment: Barclays lowered its price target from $155 to $145 and maintained an Equal Weight rating, signaling less near-term upside confidence. Analysts also cite competitive pressure in cell therapy, while Atea Pharmaceuticals reported positive hepatitis C trial data that could eventually challenge Gilead’s HCV franchise. Barclays Price Target Update

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.